We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Diaceutics Plc | LSE:DXRX | London | Ordinary Share | GB00BJQTGV64 | ORD GBP0.002 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.50 | -0.48% | 103.00 | 102.00 | 104.00 | 103.50 | 103.00 | 103.50 | 66,366 | 15:28:42 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Testing Laboratories | 19.5M | 724k | 0.0086 | 119.77 | 87.01M |
TIDMDXRX
RNS Number : 9510A
Diaceutics PLC
07 June 2021
7 June 2021
Diaceutics PLC
("Diaceutics" or "the Group")
Notice of Capital Markets Day
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces that it will be hosting a virtual Capital Markets Day ("CMD") for investors and equity analysts on Wednesday 16(th) June 2021, starting at 13:00pm BST.
The event will be hosted by Group CEO, Peter Keeling, and will include a series of presentations, a demonstration of the DXRX SaaS platform, views from an industry expert panel including:
-- Pharmaceutical Partner: a senior executive within one of the world's top five pharmaceutical companies
-- Laboratory Partner: Professor Giancarlo Pruneri, Head of Pathology Fondazione IRCCS Istituto Nazionale Tumori, Milan
-- Key Opinion Leader: Dr Avi Kulkarni, SVP and R&D leader at Nasdaq listed technology firm Cognizant
In addition, there will be a strategic update from the Company, along with a live Q&A.
A video replay of the presentation will be available via the Group's website post-event.
If you are interested in attending or have any questions relating to the Diaceutics Capital Markets Day please contact diaceutics@almapr.co.uk
Enquiries:
Diaceutics PLC www.diaceutics.com Peter Keeling, Chief Executive Officer via Alma PR Philip White, Chief Financial Officer Stifel Nicolaus Europe Limited (Nominated Adviser and Broker) Ben Maddison Stewart Wallace +44 (0)20 7710 Nick Adams 7600 Alma PR Tel: +44 (0)20 Caroline Forde 3405 0205 Robyn Fisher diaceutics@almapr.co.uk Kieran Breheny
About Diaceutics
At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network(R).
DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCFFFSIREIEIIL
(END) Dow Jones Newswires
June 07, 2021 02:00 ET (06:00 GMT)
1 Year Diaceutics Chart |
1 Month Diaceutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions